February 25, 2021 Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021
December 22, 2020 Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol
November 16, 2020 Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options
November 12, 2020 Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
November 10, 2020 Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results
November 3, 2020 Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020
October 2, 2020 Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients
August 6, 2020 Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results
July 30, 2020 Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)
